Future Phase 3 DUO-E Subgroup Data May Prove ‘Intriguing’ in Endometrial Cancer
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Trastuzumab Deruxtecan Showcases Clinical Efficacy in HER2+ Gynecological Cancers
Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.
FDA Accepts sBLA for Amivantamab/Chemo in EGFR+ Advanced/Metastatic NSCLC
Data from the phase 3 MARIPOSA-2 study support the supplemental biologics license application for amivantamab plus chemotherapy in EGFR-mutated advanced or metastatic non–small cell lung cancer.
Multidisciplinary Care and New Treatment Options in CRC
New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.
Capivasertib Combo Is Best Suited to Pathway-Altered Advanced Breast Cancer
Additional research is needed to confirm whether capivasertib/fulvestrant offers increased benefit in patients with locally advanced or metastatic breast cancer not harboring AKT pathway alterations.
Black Population Receives Worse Care Vs White Population for CRC Treatment
A study conducted by the American Cancer Society found patients who were Black received worse care for colorectal cancer treatment, with health insurance is the leading cause of racial disparities.
Tiragolumab Combo Marginally Improves ORR in PD-L1+ Cervical Cancer
Findings from the phase 2 SKYSCRAPER-04 trial support dual targeting of TIGIT and PD-L1 in patients with PD-L1–positive cervical cancer, says Ritu Salani, MD.
Enfortumab Vedotin Shows Meaningful, Sustained OS Benefit in Bladder Cancer
Data from the phase 3 EV-301 study turn up no new safety signals in patients with advanced urothelial carcinoma treated with enfortumab vedotin.
Phase 3 DUO-E Study Findings Prove ‘Exciting’ in Advanced Endometrial Cancer
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Mirvetuximab Soravtansine Yields Meaningful OS in Platinum-Resistant Ovarian Cancer
Data from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a new standard of care for patients with folate receptor α–positive, platinum-resistant ovarian cancer, says Kathleen N. Moore, MD, MS.
Induction Chemotherapy/CRT Improves Efficacy in Advanced Cervical Cancer
Results from the phase 3 GCIG INTERLACE trial highlight progression-free survival and overall survival improvements with induction chemotherapy plus chemoradiotherapy for patients with locally advanced cervical cancer.
Capivasertib Combo May Lead to QOL Improvement in Advanced HR+, HER- Breast Cancer
Paolo Tarantino, MD, gives an overview on how the recently approved combination of capivasertib plus fulvestrant can help improve treatment strategies for patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
FDA OKs Pembrolizumab/Chemo in HER2- Gastric/GEJ Cancer
First-line pembrolizumab plus chemotherapy has been approved by the FDA for patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Treatment Recommendations for Relapsed Multiple Myeloma
Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.
Dostarlimab Combo Significantly Improves PFS in Advanced Endometrial Cancer
The progression-free survival benefit of dostarlimab and chemotherapy extends to those with mismatch repair deficient or microsatellite instability–high advanced endometrial cancer.
October 2023 Snap Recap: ODAC Decision Making and Breast Cancer News
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
Radical Hysterectomies Show Sexual Toxicity in Early-Stage Cervical Cancer
Radical hysterectomies result in worse symptom experience, body image, menopausal symptoms, sexual worry, sex activity and enjoyment compared with simple hysterectomy in those with early-stage cervical cancer.
Repotrectinib Earns FDA Approval in Advanced/Metastatic ROS1+ NSCLC
Data from the phase 1/2 TRIDENT-1 trial support the FDA approval of repotrectinib for those with ROS1-positive advanced or metastatic non–small cell lung cancer.
Tisotumab Vedotin Elicits Meaningful OS Benefit in Advanced Cervical Cancer
Progression-free survival benefit appears consistent in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin.
Atezolizumab Combo Significantly Improves Survival in Cervical Cancer
Combining atezolizumab with bevacizumab and chemotherapy may be a new frontline therapy option for patients with metastatic, persistent or recurrent cervical cancer, says Ana Oaknin, MD, PhD.
Robotic Device May ‘Level the Playing Field’ in Liver Cancer Surgery
Use of the surgical Epione robot will save a significant amount of time when performing surgery for patients with liver tumors and potentially other cancers, says Govindarajan Narayanan, MD.
SONALA-001/Transcranial Ultrasound Device Gets FTD in Pediatric Brain Cancer
The preliminary safety and efficacy of SONALA-001 is being assessed as part of the SDT-201 study in diffuse intrinsic pontine glioma.
PD-L1 CDx Earns FDA Approval to Identify PD-L1+ Gastric/GEJ Tumors
Approval of PD-L1 IHC 22C3 pharmDx may also identify patients with non–small cell lung cancer and other malignancies who may benefit from treatment with pembrolizumab.
BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemia
Asher A. Chanan-Khan, MBBS, MD, led a panel discussion surround the use of Bruton tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.
Pembrolizumab/Chemo May Be New Standard in dMMR/pMMR Endometrial Cancer
Investigators report that loss of MMR mechanism is not predictive of response to chemotherapy or pembrolizumab in patients with stage III or IVA, stage IVB, or recurrent endometrial cancer.
Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case Report
A case study by Sahith Kumar Shetty, BDS, MDS, et al reviews the need for
a multidisciplinary approach to the treatment of patients with Gorlin-Goltz syndrome.
Pembrolizumab/Chemoradiation Significantly Improves PFS in Cervical Cancer
Data from the phase 3 KEYNOTE-A18 study may support pembrolizumab plus chemoradiotherapy as a new standard of care for those with newly diagnosed, high-risk, locally advanced cervical cancer.
FDA Requests Withdrawal of Copanlisib in Relapsed Follicular Lymphoma
Data from the phase 3 CHRONOS-4 study highlight that copanlisib did not reach the primary end point of progression-free survival among patients with relapsed follicular lymphoma.
DUO-E Trial Meets PFS End Point in Advanced/Recurrent Endometrial Cancer
Durvalumab plus olaparib, durvalumab monotherapy, or chemotherapy plus durvalumab saw an improvement in progression-free survival for patients with newly diagnosed advanced or recurrent endometrial cancer.
2 Clarke Drive Cranbury, NJ 08512